Why CrossBridge - CrossBridge
CrossBridge is steeped in the technology and foresight needed to overcome the challenges in healthcare today. We’re the unbiased third party needed to assure transparency of care and cost between patient, provider and payer. CrossBridge is also independent of all pharmaceutical and biotech companies. We’ve set our sights on overcoming the obstacles to the treatment of chronic inflammatory diseases, including rheumatoid and psoriatic arthritis, spondylarthrosis, lupus, irritable bowel disease, crohns and colitis, and multiple sclerosis. The CrossBridge independent, third-party solution spans the gap between providers and payers, addressing all of the challenges impeding lower cost and better outcomes for chronic inflammatory disease – and the transition to Value-Based Care.
Health plans, payers, providers, specialist physicians, cost transparency, independent of pharmaceutical and biotech companiesm, chronic inflammatory diseases, rheumatoid arthritis, psoriatic arthritis, spondylarthrosis, lupus, irritable bowel disease, crohns and colitis, multiple sclerosis.
14495
page-template,page-template-full_width,page-template-full_width-php,page,page-id-14495,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-5.0.1,vc_responsive
 

Why CrossBridge

Your Partner for Value-Based
Specialty Reimbursement

CrossBridge leadership understands the dynamics between payers, providers, pharma and patients and offers the objectivity and technological expertise to assure transparency of care and cost.

CrossBridge is also independent of pharmaceutical and biotech companies. Our platform is ideal for monitoring appropriate use and controlling the cost of the expensive specialty drugs.

 

We are unencumbered by provider/payer/pharma ownership interests…totally focused on a passion to improve care and reduce the cost of chronic inflammatory diseases including rheumatoid, psoriatic arthritis, spondyloarthrosis, inflammatory bowel disease/crohn’s, and multiple sclerosis.

17.8

MILLION

People with Chronic Inflammatory Disease (CID)

$78.8

BILLION

CID Specialty Drug Spend in the United States

The CrossBridge independent, third-party solution spans the gap between providers and payers, addressing all of the challenges impeding lower cost and better outcomes for chronic inflammatory disease – and the transition to Value-Based Care:

EXPERTISE

CrossBridge is focused on autoimmune and chronic inflammatory diseases with support from clinical advisory boards of leading specialist physicians and researchers. We are an unparalleled resource for conquering complex disease. Our expertise helps reduce variations in care, wasted dollars and improves outcomes.

INDEPENDENCE

We offer payers, providers and pharma a trusted, accomplished, independent resource for achieving better outcomes, shared risk/savings reimbursement.

 

SCALABLE

CrossBridge provides a singular SaaS platform that enables the smooth flow of clinical and cost data from payer to any specialist provider who cares for patients with complex inflammatory diseases. Similarly, our platform is scalable from providers to multiple payers. Our easy-to-use, transparent platform simplifies migration to Value-based Care and Value-based Payment..

Working together, payers, providers and CrossBridge can bring about a new era of transparency, efficiency and Value-Based Care